Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

1 year ago 43

Giuseppe Curigliano, MD, PhD, discusses findings from the phase 3 DESTINY-Breast06 trial of T-DXd in HER2-low or HER2-ultralow metastatic breast cancer.

1. Homepage
2. Breast Cancer
3. Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer